For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
No Chemotherapy in Intermediate-risk HR + HER2- Early Breast Cancer Treated with Ribociclib (NoLEEta)
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
The Canadian Cancer Trials Group (CCTG) is currently seeking applications for a Patient Representative for the Melanoma Disease Site Committee. CCTG is an inclusive organization dedicated to building a diverse network. This is a volunteer role for membership on the Melanoma Disease Site Committee, the Melanoma Disease Site Executive Committee, and the CCTG Patient Representative Committee.
Haydn Bechthold is a Law Student conducting his studies in Toronto. In 2021, at the young age of 22, Haydn received a stage 3C rectal cancer diagnosis, followed by the identification of Lynch syndrome. Because of his unique cancer journey, he has taken the admirable initiative to volunteer as a Patient Representative, supporting the Gastrointestinal Disease Site Committee at CCTG.
CCTG is happy to welcome Carol Hill who will be supporting the IND program as a Patient Representative.
Over the last six months, Centre Representatives and Contact CRAs at Canadian CCTG participating centres have been asked to share some of the challenges they’ve been experiencing around patient accrual and trial activations. This has included a Virtual Road Show of six 90-minute regional sessions and two surveys to supplement Road Show discussions and attempt to drill down on specific issues impacting accrual and trial activations, including around funding that may be impacting centres’ ability and capacity to activate and enroll patients to trials.
The Canadian Cancer Trials Group (CCTG) has now activated the symptom control trial SC29 evaluating high precision stereotactic body radiotherapy (SBRT) to conventional palliative radiotherapy (CRT) for patients with advanced cancer and a painful non-spine bone metastasis. SBRT represents a high dose treatment typically offered in the curative cancer setting; however, its role as a palliative treatment to improve pain for these patients is unknown.
